Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ENZYME PRODRUG THERAPY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 95 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Djeha, AH; Thomson, TA; Leung, H; Searle, PF; Young, LS; Kerr, DJ; Harris, PA; Mountain, A; Wrighton, CJ
      Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors

      MOLECULAR THERAPY
    2. Jain, KK
      Use of bacteria as anticancer agents

      EXPERT OPINION ON BIOLOGICAL THERAPY
    3. Tietze, LF; Herzig, T; Fecher, A; Haunert, F; Schuberth, I
      Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues forantibody-directed enzyme tumor therapy

      CHEMBIOCHEM
    4. Blackwood, L; O'Shaughnessy, PJ; Reid, SWJ; Argyle, DJ
      E. coli nitroreductase/CB1954: In vitro studies into a potential system for feline cancer gene therapy

      VETERINARY JOURNAL
    5. Xu, G; McLeod, HL
      Strategies for enzyme/prodrug cancer therapy

      CLINICAL CANCER RESEARCH
    6. Senter, PD; Beam, KS; Mixan, B; Wahl, AF
      Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

      BIOCONJUGATE CHEMISTRY
    7. Reff, ME; Heard, C
      A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    8. Sedlacek, HH
      Pharmacological aspects of targeting cancer gene therapy to endothelial cells

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    9. Ma, ZC; Taylor, JS
      Nucleic acid triggered catalytic drug and probe release: A new concept forthe design of chemotherapeutic and diagnostic agents

      BIOORGANIC & MEDICINAL CHEMISTRY
    10. McIntee, EJ; Wagner, CR
      Amino acid phosphoramidate nucleosides: Potential ADEPT/GDEPT substrates

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    11. Wong, A; Toth, I
      Lipid, sugar and liposaccharide based delivery systems

      CURRENT MEDICINAL CHEMISTRY
    12. Wardman, P
      Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia

      CURRENT MEDICINAL CHEMISTRY
    13. Hamel, W; Zirkel, D; Mehdorn, HM; Westphal, M; Israel, MA
      (E)-5-(2-bromovinyl)-2 '-deosyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells

      CANCER GENE THERAPY
    14. Karle, P; Renner, M; Salmons, B; Gunzburg, WH
      Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide

      CANCER GENE THERAPY
    15. Cui, W; Allen, ND; Skynner, M; Gusterson, B; Clark, AJ
      Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain

      GLIA
    16. Gerolami, R; Uch, R; Cardoso, J; Bagnis, C; Mannoni, P; Brechot, C
      Gene therapy for hepatocellular carcinoma. From the idea to clinical trials

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    17. Flynn, AA; Boxer, GM; Begent, RHJ; Pedley, RB
      Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    18. Monneret, C
      Recent developments in the field of antitumour anthracyclines

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    19. Sperker, B; Tomkiewicz, E; Burk, O; Barouki, R; Kroemer, HK
      Regulation of human beta-glucoronidase by A23187 and thapsigargin in the hepatoma cell line HepG2

      MOLECULAR PHARMACOLOGY
    20. Lovering, AL; Hyde, EI; Searle, PF; Scott, AW
      The structure of Escherichia coli nitroreductase complexed with nicotinic acid: Three crystal forms at 1.7 (A)over-circle, 1.8 (A)over-circle and 2.4(A)over-circle resolution

      JOURNAL OF MOLECULAR BIOLOGY
    21. Greco, O; Dachs, GU
      Gene directed Enzyme/Prodrug therapy of cancer: Historical appraisal and future prospectives

      JOURNAL OF CELLULAR PHYSIOLOGY
    22. Spooner, RA; Maycroft, KA; Paterson, H; Friedlos, F; Springer, CJ; Marais, R
      Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy

      INTERNATIONAL JOURNAL OF CANCER
    23. Houba, PHJ; Boven, E; van der Meulen-Muileman, IH; Leenders, RGG; Scheeren, JW; Pinedo, HM; Haisma, HJ
      Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate

      INTERNATIONAL JOURNAL OF CANCER
    24. Azoulay, M; Chalard, F; Gesson, JP; Florent, JC; Monneret, C
      2-nitro and 4-nitro-quinone-methides are not irreversible inhibitors of bovine beta-glucuronidase

      CARBOHYDRATE RESEARCH
    25. Pedley, RB; Hill, SA; Boxer, GM; Flynn, AA; Boden, R; Watson, R; Dearling, J; Chaplin, DJ; Begent, RHJ
      Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate

      CANCER RESEARCH
    26. Monks, NR; Blakey, DC; Curtin, NJ; East, SJ; Heuze, A; Newell, DR
      Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

      BRITISH JOURNAL OF CANCER
    27. Folkes, LK; Wardman, P
      Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy

      BIOCHEMICAL PHARMACOLOGY
    28. Ho, JJL
      Mucins in the diagnosis and therapy of pancreatic cancer

      CURRENT PHARMACEUTICAL DESIGN
    29. Bramhall, SR
      Novel non-operative treatment and treatment strategies in pancreatic cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    30. Burke, PJ
      The potential use of carboxypeptidase G(2) in the treatment of cancer

      EXPERT OPINION ON THERAPEUTIC PATENTS
    31. Bishop, A; Buzko, O; Heyeck-Dumas, S; Jung, I; Kraybill, B; Liu, Y; Shah, K; Ulrich, S; Witucki, L; Yang, F; Zhang, C; Shokat, KM
      Unnatural ligands for engineered proteins: New tools for chemical genetics

      ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE
    32. Weiner, LM; Adams, GP
      New approaches to antibody therapy

      ONCOGENE
    33. Djeha, AH; Hulme, A; Dexter, MT; Mountain, A; Young, LS; Searle, PF; Kerr, DJ; Wrighton, CJ
      Expression of Escherichia coli B nitroreductase in established human tumorxenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

      CANCER GENE THERAPY
    34. Poulain, L; Ziller, C; Muller, CD; Erbacher, P; Bettinger, T; Rodier, JF; Behr, JP
      Ovarian carcinoma cells are effectively transfected by polyethylenimine (PEI) derivatives

      CANCER GENE THERAPY
    35. Greco, O; Folkes, LK; Wardman, P; Tozer, GM; Dachs, GU
      Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid

      CANCER GENE THERAPY
    36. Spooner, RA; Martin, J; Friedlos, F; Marais, R; Springer, CJ
      In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug

      CANCER GENE THERAPY
    37. Westphal, EM; Ge, JQ; Catchpole, JR; Ford, M; Kenney, SC
      The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: Induction of bystander killing in vitro and in vivo

      CANCER GENE THERAPY
    38. Vogt, J; Perozzo, R; Pautsch, A; Prota, A; Schelling, P; Pilger, P; Folkers, G; Scapozza, L; Schulz, GE
      Nucleoside binding site of Herpes simplex type 1 thymidine kinase analyzedby X-ray crystallography

      PROTEINS-STRUCTURE FUNCTION AND GENETICS
    39. Krackhardt, A; Schwartz, S; Thiel, E
      Targeting folates by carboxypeptidase G2: Potential applications in anticancer therapy

      ONKOLOGIE
    40. Kestell, P; Pruijn, FB; Siim, BG; Palmer, BD; Wilson, WR
      Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    41. Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DIR; Cooke, SP; Flynn, AA; Sharma, SK; Boxer, G; Pedley, RB; Begent, RHJ
      Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    42. Sykes, BM; Hay, MP; Bohinc-Herceg, D; Helsby, NA; O'Connor, CJ; Denny, WA
      Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    43. Chester, KA; Bhatia, J; Boxer, G; Cooke, SP; Flynn, AA; Huhalov, A; Mayer, A; Pedley, RB; Robson, L; Sharma, SK; Spencer, DIR; Begent, RHJ
      Clinical applications of phage-derived sFvs and sFv fusion proteins

      DISEASE MARKERS
    44. Castro, MG; Cowen, R; Smith-Arica, J; Williams, J; Ali, S; Windeatt, S; Gonzalez-Nicolini, V; Maleniak, T; Lowenstein, PR
      Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas

      HISTOLOGY AND HISTOPATHOLOGY
    45. Saleem, A; Aboagye, EO; Price, PM
      In vivo monitoring of drugs using radiotracer techniques

      ADVANCED DRUG DELIVERY REVIEWS
    46. Banfi, L; Guanti, G
      Synthesis of a methoxy-substituted lactenediyne

      TETRAHEDRON LETTERS
    47. Smyth, TP; O'Donnell, ME; O'Connor, MJ; St Ledger, JO
      beta-lactamase-dependent prodrugs - Recent developments

      TETRAHEDRON
    48. Queiroz, EF; Roblot, F; Duret, P; Figadere, B; Gouyette, A; Laprevote, O; Serani, L; Hocquemiller, R
      Synthesis, spectroscopy, and cytotoxicity of glycosylated acetogenin derivatives as promising molecules for cancer therapy

      JOURNAL OF MEDICINAL CHEMISTRY
    49. Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; Michael, NP; Begent, RHJ
      Catalytic activity of an in vivo tumor targeted anti-CEA scFv :: carboxypeptidase G2 fusion protein

      INTERNATIONAL JOURNAL OF CANCER
    50. Monneret, C; Florent, JC
      Immunotargeting of antitumor drugs

      BULLETIN DU CANCER
    51. Manu, M; Buckels, J; Bramhall, S
      Molecular technology and pancreatic cancer

      BRITISH JOURNAL OF SURGERY
    52. Roche, VF
      Antineoplastic immunoconjugates and immunotoxins

      AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION
    53. Anderson, D; Ferry, DR; Knox, RJ; Andrews, SJ; Downes, AJ; Kerr, DJ; Seymour, LW
      High-performance liquid chromatographic method for sensitive determinationof the alkylating agent CB1954 in human plasma

      JOURNAL OF CHROMATOGRAPHY B
    54. Jaffar, M; Stratford, IJ
      Bioreductive drugs: selectivity towards hypoxic tissue

      EXPERT OPINION ON THERAPEUTIC PATENTS
    55. Patterson, A; Harris, AL
      Molecular chemotherapy for breast cancer

      DRUGS & AGING
    56. Lu, JY; Lowe, DA; Kennedy, MD; Low, PS
      Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug

      JOURNAL OF DRUG TARGETING
    57. Cheng, TL; Wu, PY; Wu, MF; Chern, JW; Roffler, SR
      Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM

      BIOCONJUGATE CHEMISTRY
    58. Hamstra, DA; Rehemtulla, A
      Toward an enzyme/prodrug strategy for cancer gene therapy: Endogenous activation of carboxypeptidase A mutants by the PACE/furin family of propeptidases

      HUMAN GENE THERAPY
    59. Mehta, LK; Hobbs, S; Chen, S; Knox, RJ; Parrick, J
      Phthalimide analogs of CB 1954: synthesis and bioactivation

      ANTI-CANCER DRUGS
    60. Waxman, DJ; Chen, L; Hecht, JED; Jounaidi, Y
      Cytochrome P450-based cancer gene therapy: Recent advances and future prospects

      DRUG METABOLISM REVIEWS
    61. Crystal, RG
      In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    62. Jackson, TL; Lubkin, SR; Murray, JD
      Theoretical analysis of conjugate localization in two-step cancer chemotherapy

      JOURNAL OF MATHEMATICAL BIOLOGY
    63. Desbene, S; Van, HDT; Michel, S; Tillequin, F; Koch, M; Schmidt, F; Florent, JC; Monneret, C; Straub, R; Czech, J; Gerken, M; Bosslet, K
      Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy

      ANTI-CANCER DRUG DESIGN
    64. Mayer, A; Chester, KA; Flynn, AA; Begent, RHJ
      Taking engineered anti-CEA antibodies to the clinic

      JOURNAL OF IMMUNOLOGICAL METHODS
    65. Cheng, TL; Wei, SL; Chen, BM; Chern, JW; Wu, MF; Liu, PW; Roffler, SR
      Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

      BRITISH JOURNAL OF CANCER
    66. Chou, WC; Liao, KW; Lo, YC; Jiang, SY; Yeh, MY; Roffler, SR
      Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells

      BIOTECHNOLOGY AND BIOENGINEERING
    67. Fonseca, MJ; Haisma, HJ; Klaasen, S; Vingerhoeds, MH; Storm, G
      Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties

      BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
    68. TILBY MJ; MCCARTNEY H; GOULD KA; OHARE CC; HARTLEY JA; HALL AG; GOLDING BT; LAWLEY PD
      A MONOFUNCTIONAL DERIVATIVE OF MELPHALAN - PREPARATION, DNA ALKYLATION PRODUCTS, AND DETERMINATION OF THE SPECIFICITY OF MONOCLONAL-ANTIBODIES THAT RECOGNIZE MELPHALAN-DNA ADDUCTS

      Chemical research in toxicology
    69. RAUTH AM; MELO T; MISRA V
      BIOREDUCTIVE THERAPIES - AN OVERVIEW OF DRUGS AND THEIR MECHANISMS OFACTION

      International journal of radiation oncology, biology, physics
    70. WARRINGTON KH; TESCHENDORF C; CAO LG; MUZYCZKA N; SIEMANN DW
      DEVELOPING VDEPT FOR DT-DIAPHORASE (NQO1) USING AN AAV VECTOR PLASMID

      International journal of radiation oncology, biology, physics
    71. FOLKES LK; CANDEIAS LP; WARDMAN P
      TOWARD TARGETED OXIDATION THERAPY OF CANCER - PEROXIDASE-CATALYZED CYTOTOXICITY OF INDOLE-3-ACETIC ACIDS

      International journal of radiation oncology, biology, physics
    72. HAISMA HJ; BRAKENHOFF RH; VANDERMEULENMUILEMAN I; PINEDO HM; BOVEN E
      CONSTRUCTION AND CHARACTERIZATION OF A FUSION PROTEIN OF SINGLE-CHAINANTI-CARCINOMA ANTIBODY 323 A3 AND HUMAN BETA-GLUCURONIDASE/

      Cancer immunology and immunotherapy
    73. WITTE CP; BLASCO R; CASTILLO F
      MICROBIAL PHOTODEGRADATION OF AMINOARENES METABOLISM OF 2-AMINO-4-NITROPHENOL BY RHODOBACTER-CAPSULATUS

      Applied biochemistry and biotechnology
    74. Edge, M; Forder, C; Hennam, J; Lee, I; Tonge, D; Hardern, I; Fitton, J; Eckersley, K; East, S; Shufflebotham, A; Blakey, D; Slater, A
      Engineered human carboxypeptidase B enzymes that hydrolyse hippuryl-L-glutamic acid: reversed-polarity mutants

      PROTEIN ENGINEERING
    75. LEMMON MJ; VANZIJL P; FOX ME; MAUCHLINE ML; GIACCIA AJ; MINTON NP; BROWN JM
      ANAEROBIC-BACTERIA AS A GENE DELIVERY SYSTEM THAT IS CONTROLLED BY THE TUMOR MICROENVIRONMENT

      Gene therapy
    76. DACHS GU; DOUGHERTY GJ; STRATFORD IJ; CHAPLIN DJ
      TARGETING GENE-THERAPY TO CANCER - A REVIEW

      Oncology research
    77. SIIM BG; DENNY WA; WILSON WR
      NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION

      Oncology research
    78. GREEN NK; YOUNGS DJ; NEOPTOLEMOS JP; FRIEDLOS F; KNOX RJ; SPRINGER CJ; ANLEZARK GM; MICHAEL NP; MELTON RG; FORD MJ; YOUNG LS; KERR DJ; SEARLE PF
      SENSITIZATION OF COLORECTAL AND PANCREATIC-CANCER CELL-LINES TO THE PRODRUG 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) BY RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE ESCHERICHIA-COLI NITROREDUCTASE GENE

      Cancer gene therapy
    79. BERRY JM; WATSON CY; WHISH WJD; THREADGILL MD
      5-NITROFURAN-2-YLMETHYL GROUP AS A POTENTIAL BIOREDUCTIVELY ACTIVATEDPRO-DRUG SYSTEM

      Journal of the Chemical Society. Perkin transactions. I
    80. STORM G; VINGERHOEDS MH; CROMMELIN DJA; HAISMA HJ
      IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF ANTICANCER PRODRUGS

      Advanced drug delivery reviews
    81. FOX ME; LEMMON MJ; MAUCHLINE ML; DAVIS TO; GIACCIA AJ; MINTON NP; BROWN JM
      ANAEROBIC-BACTERIA AS A DELIVERY SYSTEM FOR CANCER GENE-THERAPY - IN-VITRO ACTIVATION OF 5-FLUOROCYTOSINE BY GENETICALLY-ENGINEERED CLOSTRIDIA

      Gene therapy
    82. MARINI FC; PAN BF; NELSON JA; LAPEYRE JN
      THE DRUG VERAPAMIL INHIBITS BYSTANDER KILLING BUT NOT CELL SUICIDE INTHYMIDINE KINASE GANCICLOVIR PRODRUG-ACTIVATED GENE-THERAPY

      Cancer gene therapy
    83. TUCKER AD; ROWSELL S; MELTON RG; PAUPTIT RA
      A NEW CRYSTAL FORM OF CARBOXYPEPTIDASE G(2) FROM PSEUDOMONAS SP STRAIN RS-16 WHICH IS MORE AMENABLE TO STRUCTURE DETERMINATION

      Acta crystallographica. Section D, Biological crystallography
    84. VINGERHOEDS MH; HAISMA HJ; BELLIOT SO; SMIT RHP; CROMMELIN DJA; STORM G
      IMMUNOLIPOSOMES AS ENZYME-CARRIERS (IMMUNO-ENZYMOSOMES) FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - OPTIMIZATION OF PRODRUG ACTIVATING CAPACITY

      Pharmaceutical research
    85. ATWELL GJ; BOYD M; PALMER BD; ANDERSON RF; PULLEN SM; WILSON WR; DENNY WA
      SYNTHESIS AND EVALUATION OF 4-SUBSTITUTED ANALOGS OF 5-[N,N-BIS(2-CHLOROETHYL)AMINO]2-NITROBENZAMIDE AS BIOREDUCTIVELY ACTIVATED PRODRUGS USING AN ESCHERICHIA-COLI NITROREDUCTASE

      Anti-cancer drug design
    86. SHARMA SK
      ACCELERATED CLEARANCE SYSTEMS

      Advanced drug delivery reviews
    87. SENTER PD; SVENSSON HP
      A SUMMARY OF MONOCLONAL ANTIBODY-ENZYME PRODRUG/

      Advanced drug delivery reviews
    88. SINHABABU AK; THAKKER DR
      PRODRUGS OF ANTICANCER AGENTS

      Advanced drug delivery reviews
    89. LARDEN DW; CHEUNG HTA
      SYNTHESIS OF N-ALPHA-AMINOACYL DERIVATIVES OF MELPHALAN FOR POTENTIALUSE IN DRUG TARGETING

      Tetrahedron letters
    90. DENNY WA; WILSON WR; HAY MP
      RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS

      British Journal of Cancer
    91. MINTON NP; MAUCHLINE ML; LEMMON MJ; BREHM JK; FOX M; MICHAEL NP; GIACCIA A; BROWN JM
      CHEMOTHERAPEUTIC TUMOR TARGETING USING CLOSTRIDIAL SPORES

      FEMS microbiology reviews
    92. BLAKEY DC; DAVIES DH; DOWELL RI; EAST SJ; BURKE PJ; SHARMA SK; SPRINGER CJ; MAUGER AB; MELTON RG
      ANTITUMOR EFFECTS OF AN ANTIBODY-CARBOXYPEPTIDASE G2 CONJUGATE IN COMBINATION WITH PHENOL MUSTARD PRODRUGS

      British Journal of Cancer
    93. SMAL MA; DONG Z; CHEUNG HTA; ASANO Y; ESCOFFIER L; COSTELLO M; TATTERSALL MHN
      ACTIVATION AND CYTOTOXICITY OF 2-ALPHA-AMINOACYL PRODRUGS OF METHOTREXATE

      Biochemical pharmacology
    94. SHARMA SK; BAGSHAWE KD; BURKE PJ; BODEN JA; ROGERS GT; SPRINGER CJ; MELTON RG; SHERWOOD RF
      GALACTOSYLATED ANTIBODIES AND ANTIBODY-ENZYME CONJUGATES IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY

      Cancer
    95. VINGERHOEDS MH; HAISMA HJ; VANMUIJEN M; VANDERIJT RBJ; CROMMELIN DJA; STORM G
      A NEW APPLICATION FOR LIPOSOMES IN CANCER-THERAPY - IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF PRODRUGS

      FEBS letters


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 19:59:56